Holger Gieschen, MD
Radiation Oncology · Memphis, TNNPI 1295738680
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. Teleflex LLC accounts for 72.3% of it on its own, with 6 other manufacturers making up the rest. 2024 is the largest year on record at $872, more than ten times the $44 reported in 2019.
Across 9 payments — averaging $134.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$872
- GT Medical Technologies, Inc$131
- Regeneron Healthcare Solutions, Inc.$122
- Daiichi Sankyo Inc.$26
- Pfizer$21
- Elekta, Inc.$18
- plus $17 from 1 others
What the payments were for
- Travel & lodging$54245%
- Food & beverage$64353%
- Education$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 3 | $872 |
| GT Medical Technologies, Inc | 1 | $131 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Pfizer | 1 | $21 |
| Elekta, Inc. | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,206 in reported general payments places this provider in the 65th percentile of 115 radiation oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 84 | $1,016 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $8 |
| Lorazepam | 12 | $7 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Memphis
- David RobergeMemphis$28K
- Matthew BalloMemphis$25K
- Daniel WakefieldMemphis$9K
- Thomas MerchantMemphis$6K
- David SchwartzMemphis$3K
- Shelby LaneMemphis$2K
- Angela WorthamMemphis$714
- Han-Chih ChangNashville$66K
- Karen WinkfieldNashville$53K
- James GrayNashville$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.